$HCTI
Healthcare Triangle, Inc.

2024 Q1 Form 10-K Financial Statement

#000121390024023562 Filed on March 18, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $4.109M $7.060M $33.20M
YoY Change -58.23% -37.48% -27.64%
Cost Of Revenue $3.095M $5.530M $26.43M
YoY Change -62.46% -41.65% -23.6%
Gross Profit $1.070B $1.530M $1.070B
YoY Change 67068.86% -15.66% 9373.22%
Gross Profit Margin 26040.4% 21.67% 3222.6%
Selling, General & Admin $2.059M $1.602M $10.09M
YoY Change -39.24% -44.66%
% of Gross Profit 0.19% 104.71% 0.94%
Research & Development $127.0K $104.0K $799.0K
YoY Change -76.44% -96.25% -86.58%
% of Gross Profit 0.01% 6.8% 0.07%
Depreciation & Amortization $11.00K $4.844M $7.232M
YoY Change -98.74% 432.31% 114.34%
% of Gross Profit 0.0% 316.6% 0.68%
Operating Expenses $2.722M $6.550M $18.13M
YoY Change -43.32% -0.38% -16.52%
Operating Profit -$1.708M -$5.020M -$11.35M
YoY Change -46.77% 5.44% 8.95%
Interest Expense -$149.0K -$305.0K -$968.0K
YoY Change -340.32% 267.47% -556.6%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 $12.00K
YoY Change -100.0% -100.0% -98.89%
Pretax Income -$1.857M -$5.325M -$12.30M
YoY Change -43.02% 9.79% 28.88%
Income Tax $5.000K $7.000K $35.00K
% Of Pretax Income
Net Earnings -$1.862M -$5.332M -$12.34M
YoY Change -43.2% 9.64% 28.4%
Net Earnings / Revenue -45.32% -75.52% -37.16%
Basic Earnings Per Share -$0.42 -$2.92
Diluted Earnings Per Share -$0.42 -$1.26 -$2.92
COMMON SHARES
Basic Shares Outstanding 4.650M shares 4.278M shares 4.229M shares
Diluted Shares Outstanding 4.455M shares 4.229M shares

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $301.0K $1.234M $1.234M
YoY Change 12.73% -7.98% -7.98%
Cash & Equivalents $301.0K $1.234M $1.234M
Short-Term Investments
Other Short-Term Assets $773.0K $1.259M $1.259M
YoY Change 16.94% 54.29% 54.29%
Inventory
Prepaid Expenses
Receivables $2.095M $3.236M $3.236M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $3.169M $5.729M $5.729M
YoY Change -50.79% -26.07% -26.07%
LONG-TERM ASSETS
Property, Plant & Equipment $33.00K $44.00K $44.00K
YoY Change -50.75% -45.0% -45.0%
Goodwill
YoY Change
Intangibles $3.637M $3.611M
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $3.703M $4.320M $4.320M
YoY Change -70.19% -66.8% -66.8%
TOTAL ASSETS
Total Short-Term Assets $3.169M $5.729M $5.729M
Total Long-Term Assets $3.703M $4.320M $4.320M
Total Assets $6.872M $10.05M $10.05M
YoY Change -63.56% -51.6% -51.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.013M $1.953M $1.953M
YoY Change 54.02% 31.87% 31.87%
Accrued Expenses $0.00 $0.00
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $1.795M $3.429M $3.429M
YoY Change -39.05% 42.16% 42.16%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.995M $8.123M $8.123M
YoY Change -18.21% 32.12% 32.12%
LONG-TERM LIABILITIES
Long-Term Debt $888.0K $888.0K $888.0K
YoY Change
Other Long-Term Liabilities $500.0K $500.0K $500.0K
YoY Change -77.55% -77.54% -77.54%
Total Long-Term Liabilities $1.388M $1.388M $1.388M
YoY Change -37.67% -37.66% -37.66%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.995M $8.123M $8.123M
Total Long-Term Liabilities $1.388M $1.388M $1.388M
Total Liabilities $7.383M $9.511M $9.511M
YoY Change -22.75% 13.56% 13.57%
SHAREHOLDERS EQUITY
Retained Earnings -$26.77M -$24.91M
YoY Change 68.95% 98.16%
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$511.0K $538.0K $538.0K
YoY Change
Total Liabilities & Shareholders Equity $6.872M $10.05M $10.05M
YoY Change -63.56% -51.6% -51.6%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$1.862M -$5.332M -$12.34M
YoY Change -43.2% 9.64% 28.4%
Depreciation, Depletion And Amortization $11.00K $4.844M $7.232M
YoY Change -98.74% 432.31% 114.34%
Cash From Operating Activities -$50.00K $1.214M -$1.612M
YoY Change -96.88% -154.49% -38.0%
INVESTING ACTIVITIES
Capital Expenditures $6.000K $13.00K
YoY Change -57.14% -99.61%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities -$6.000K -$13.00K
YoY Change -57.14% -99.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net -$500.0K
YoY Change -91.3%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$883.0K -49.00K $1.518M
YoY Change -265.67% -91.27% -72.35%
NET CHANGE
Cash From Operating Activities -$50.00K 1.214M -$1.612M
Cash From Investing Activities -6.000K -$13.00K
Cash From Financing Activities -$883.0K -49.00K $1.518M
Net Change In Cash -$933.0K 1.159M -$107.0K
YoY Change -13.13% -141.35% -75.06%
FREE CASH FLOW
Cash From Operating Activities -$50.00K $1.214M -$1.612M
Capital Expenditures $6.000K $13.00K
Free Cash Flow -$50.00K $1.208M -$1.625M
YoY Change -96.89% -153.88% -72.55%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-40903
CY2023 dei Entity Registrant Name
EntityRegistrantName
HEALTHCARE TRIANGLE, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3559776
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
7901 Stoneridge Drive
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 220
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Pleasanton
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94588
CY2023 dei City Area Code
CityAreaCode
(925)
CY2023 dei Local Phone Number
LocalPhoneNumber
270-4812
CY2023 dei Security12b Title
Security12bTitle
Common Stock, $0.00001 par value
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
3723021 usd
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4649909 shares
CY2023 dei Auditor Name
AuditorName
BF Borgers CPA PC
CY2023 dei Auditor Firm
AuditorFirmId
5041
CY2023 dei Auditor Location
AuditorLocation
Lakewood, CO
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1234000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1341000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3236000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5592000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1259000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
816000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
5729000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
7749000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
44000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
80000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
1289000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3972000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
10570000 usd
CY2023Q4 us-gaap Assets
Assets
10049000 usd
CY2022Q4 us-gaap Assets
Assets
20763000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1953000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1481000 usd
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
954000 usd
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
55000 usd
CY2023Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
3429000 usd
CY2022Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
2412000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1787000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2200000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8123000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6148000 usd
CY2023Q4 us-gaap Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
500000 usd
CY2022Q4 us-gaap Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
2227000 usd
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
888000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
9511000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
8375000 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4308822 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4308822 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4170953 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4170953 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
25443000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24956000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24905000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-12568000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
538000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12388000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10049000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20763000 usd
CY2023 us-gaap Revenues
Revenues
33203000 usd
CY2022 us-gaap Revenues
Revenues
45886000 usd
CY2023 us-gaap Cost Of Revenue
CostOfRevenue
26426000 usd
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
34591000 usd
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
799000 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5954000 usd
CY2023 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4670000 usd
CY2022 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6808000 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5424000 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5575000 usd
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
7232000 usd
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3374000 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
18125000 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
21711000 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-11348000 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-10416000 usd
CY2023 us-gaap Other Income
OtherIncome
12000 usd
CY2022 us-gaap Other Income
OtherIncome
1081000 usd
CY2023 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-968000 usd
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-212000 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12304000 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9547000 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
35000 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
63000 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-12339000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-9610000 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.92
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.63
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4228741 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3659095 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
16135000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-9610000 usd
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
257000 usd
CY2022 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
125000 usd
CY2022 hcti Stock Issued During Period Value Issuance Of Common Stock In Connection With Private Placement
StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivatePlacement
3580000 usd
CY2022 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
2308000 usd
CY2022 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
141000 usd
CY2022 hcti Stock Issued During Period Value Cash Collected On Common Stock Options
StockIssuedDuringPeriodValueCashCollectedOnCommonStockOptions
29000 usd
CY2022 hcti Stock Issued During Period Value Prior Period Adjustment
StockIssuedDuringPeriodValuePriorPeriodAdjustment
-296000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12388000 usd
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17000 usd
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
500000 usd
CY2023 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
176000 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-12339000 usd
CY2023 hcti Stock Issued During Period Value Adjustments
StockIssuedDuringPeriodValueAdjustments
-203000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
538000 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-12339000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-9610000 usd
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7232000 usd
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3374000 usd
CY2023 hcti Common Stock Issued For Service
CommonStockIssuedForService
51000 usd
CY2022 hcti Common Stock Issued For Service
CommonStockIssuedForService
125000 usd
CY2022 hcti Income From Ppp
IncomeFromPPP
-1069000 usd
CY2022 hcti Interest On Leases Paymentpayroll Protection Program
InterestOnLeasesPaymentpayrollProtectionProgram
17000 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
17000 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
257000 usd
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2356000 usd
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-4081000 usd
CY2023 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
443000 usd
CY2022 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
454000 usd
CY2023 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-771000 usd
CY2022 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
259000 usd
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
472000 usd
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-392000 usd
CY2023 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
271000 usd
CY2022 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
1330000 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1612000 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2600000 usd
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13000 usd
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
40000 usd
CY2022 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
3279000 usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13000 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3319000 usd
CY2022 hcti Increase In Capital
IncreaseInCapital
0 usd
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
29000 usd
CY2023 us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
1018000 usd
CY2022 us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
203000 usd
CY2022 hcti Taxes Paid
TaxesPaid
294000 usd
CY2022 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
194000 usd
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
500000 usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5888000 usd
CY2022 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
142000 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1518000 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5490000 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-107000 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-429000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1341000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1770000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1234000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1341000 usd
CY2023 us-gaap Interest Paid Net
InterestPaidNet
968000 usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
212000 usd
CY2023 us-gaap Income Taxes Paid
IncomeTaxesPaid
35000 usd
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
63000 usd
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements is in conformity with GAAP which requires us to make estimates, judgments and assumptions that affect the financial statements and the notes thereto. These estimates are based on information available as of the date of the financial statements. On a regular basis, management evaluates these estimates and assumptions. Items subject to such estimates and assumptions include, but are not limited to:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td>the standalone selling price for each distinct performance obligation</td></tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td>the determination of the period of benefit for amortization of deferred costs</td></tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td>the fair value of assets acquired, and liabilities assumed for business combinations.</td></tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td>Share based compensation including warrants</td></tr></table>
CY2023 us-gaap Gross Profit
GrossProfit
1070000000.00 usd
CY2023Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
1000000000 usd
CY2023 us-gaap Revenues
Revenues
33203000 usd
CY2022 us-gaap Revenues
Revenues
45886000 usd
CY2023 hcti Changes Amount Revenue
ChangesAmountRevenue
-12683000 usd
CY2023 hcti Changes Percentage Revenue
ChangesPercentageRevenue
-0.28 pure
CY2023 us-gaap Profit Loss
ProfitLoss
-401000 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-1389000 usd
CY2022 hcti Changes Amount Total Segment Operating Profitloss
ChangesAmountTotalSegmentOperatingProfitloss
988000 usd
CY2022 hcti Total Segment Operating Profit Percentage Changes
TotalSegmentOperatingProfitPercentageChanges
-0.71 pure
CY2023 hcti Unallocated Costsvalue
UnallocatedCostsvalue
10947000 usd
CY2022 hcti Unallocated Costsvalue
UnallocatedCostsvalue
9027000 usd
CY2022 hcti Changes Amount Unallocated Costs
ChangesAmountUnallocatedCosts
1920000 usd
CY2022 hcti Less Unallocated Costs Percentage Changes
LessUnallocatedCostsPercentageChanges
0.21 pure
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-11348000 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-10416000 usd
CY2022 hcti Changes Amount Income From Operations
ChangesAmountIncomeFromOperations
-932000 usd
CY2022 hcti Income From Operations Percentage Changes
IncomeFromOperationsPercentageChanges
-0.09 pure
CY2023 us-gaap Other Noncash Income
OtherNoncashIncome
12000 usd
CY2022 us-gaap Other Noncash Income
OtherNoncashIncome
1081000 usd
CY2022 hcti Changes Amount Other Income
ChangesAmountOtherIncome
-1069000 usd
CY2022 hcti Other Income Percentage Changes
OtherIncomePercentageChanges
-0.99 pure
CY2023 us-gaap Interest Expense Debt
InterestExpenseDebt
968000 usd
CY2022 us-gaap Interest Expense Debt
InterestExpenseDebt
212000 usd
CY2022 hcti Changes Amount Interest Expense
ChangesAmountInterestExpense
-757000 usd
CY2022 hcti Interest Expense Percentage Changes
InterestExpensePercentageChanges
-3.59 pure
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12304000 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9547000 usd
CY2022 hcti Changes Amount Netloss Before Income Tax
ChangesAmountNetlossBeforeIncomeTax
-2757000 usd
CY2022 hcti Net Income Loss Before Income Tax Expenses Percentage Changes
NetIncomeLossBeforeIncomeTaxExpensesPercentageChanges
-0.29 pure
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3236000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5592000 usd
CY2024Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
3025000 usd
CY2023 us-gaap Asset Acquisition Consideration Transferred Contingent Consideration
AssetAcquisitionConsiderationTransferredContingentConsideration
120000 usd
CY2024Q1 us-gaap Goodwill Impairment Loss Net Of Tax
GoodwillImpairmentLossNetOfTax
1170000 usd
CY2023 us-gaap Goodwill Impairment Loss Net Of Tax
GoodwillImpairmentLossNetOfTax
1290000 usd
CY2022 us-gaap Goodwill Impairment Loss Net Of Tax
GoodwillImpairmentLossNetOfTax
0 usd
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
954000 usd
CY2023Q4 us-gaap Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
500000 usd
CY2023 us-gaap Advertising Expense
AdvertisingExpense
0 usd
CY2022 us-gaap Advertising Expense
AdvertisingExpense
0 usd
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Concentrations</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and trade receivables. Credit risks associated with trade receivables is minimal due to the Company’s customer base which consist of large customer base and ongoing procedures, which monitor the credit worthiness of its customers. For the year ended December 31, 2023 and 2022 sales to five major customers accounted for approximately 77% and 72% of total revenue respectively. For the year ended December 31, 2023 and year ended December 31, 2022 accounts receivable from five major customers accounted for approximately 78% and 72% of the total accounts receivables.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains cash balances in various financial institutions. The balances are generally insured by the Federal Deposit Insurance Corporation up to $250,000 (valid through December 31, 2023) per institution.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, and 2022, The Company had $667 and $652, respectively, of uninsured cash balances. the Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash.</p>
CY2023Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000000 usd
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
667000 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
652000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
132000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
119000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
88000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
39000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
44000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
80000 usd
CY2023 us-gaap Depreciation
Depreciation
48000 usd
CY2022 us-gaap Depreciation
Depreciation
35000 usd
CY2021Q4 hcti Lease Expense
LeaseExpense
176000 usd
CY2022 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
4000 usd
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
180000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
16473000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8890000 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3611000 usd
CY2023 hcti Finite Lived Intangible Assets Deletions
FiniteLivedIntangibleAssetsDeletions
3972000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
16473000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5903000 usd
CY2022 hcti Finite Lived Intangible Assets Deletions
FiniteLivedIntangibleAssetsDeletions
10570000 usd
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1783000 usd
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1963000 usd
CY2023 us-gaap Contract With Customer Asset Credit Loss Expense
ContractWithCustomerAssetCreditLossExpense
585000000 usd
CY2023Q4 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
3025000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1343000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1343000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1286000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3972000 usd
CY2023 us-gaap Payments For Rent
PaymentsForRent
0 usd
CY2022 us-gaap Payments For Rent
PaymentsForRent
180000 usd
CY2022 us-gaap Payments For Leasing Costs
PaymentsForLeasingCosts
180000 usd
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
344000 usd
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P12M
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0475 pure
CY2023 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
377000 usd
CY2022 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
197000 usd
CY2023 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
235000 usd
CY2022 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
180000 usd
CY2022 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
3279000 usd
CY2023 us-gaap Initial Offering Period
InitialOfferingPeriod
three
CY2023Q4 hcti Due From Other Related Parties Noncurrents
DueFromOtherRelatedPartiesNoncurrents
650000 usd
CY2022Q4 hcti Due From Other Related Parties Noncurrents
DueFromOtherRelatedPartiesNoncurrents
0 usd
CY2023 hcti Unvested Common Stock
UnvestedCommonStock
8372 shares
CY2023 hcti Earnout Payment
EarnoutPayment
2500000 usd
CY2023Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
2209000 usd
CY2023 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2022-03-31
CY2023Q4 us-gaap Goodwill Gross
GoodwillGross
1289000 usd
CY2023Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Indefinite Lived Intangible Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
6018000 usd
CY2023Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
1289000 usd
CY2023Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
970000 usd
CY2023Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
3142000 usd
CY2023Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
11419000 usd
CY2023Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
758000 usd
CY2023Q4 hcti Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Short Term Borrowing
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermBorrowing
2209000 usd
CY2023Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther
679000 usd
CY2023Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
3646000 usd
CY2023Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
7773000 usd
CY2023Q4 hcti Business Combinations Total Purchase Price
BusinessCombinationsTotalPurchasePrice
7773000 usd
CY2022Q4 us-gaap Business Combination Contingent Consideration Asset
BusinessCombinationContingentConsiderationAsset
625000 usd
CY2023Q4 us-gaap Business Combination Contingent Consideration Asset
BusinessCombinationContingentConsiderationAsset
0 usd
CY2023 us-gaap Asset Acquisition Consideration Transferred Other Assets
AssetAcquisitionConsiderationTransferredOtherAssets
125000 usd
CY2023 us-gaap Business Combination Consideration Transferred Other1
BusinessCombinationConsiderationTransferredOther1
500000 usd
CY2023Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10.66
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
10.65
CY2023Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
37682 shares
CY2023Q4 us-gaap Share Price
SharePrice
6.2
CY2023Q4 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
141000 usd
CY2023Q4 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
4420000000 usd
CY2023Q4 hcti Notes Face Value Percentage
NotesFaceValuePercentage
0.50 pure
CY2023 hcti Fund Received
FundReceived
5200000 usd
CY2023 hcti Number Of Shares Convertible Note Issued Percentage
NumberOfSharesConvertibleNoteIssuedPercentage
0.50 pure
CY2023Q4 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
28.8
CY2023 hcti Percentage Of Common Stock Underlying Such Warrant
PercentageOfCommonStockUnderlyingSuchWarrant
0.25 pure
CY2023Q4 us-gaap Debt Instrument Annual Principal Payment
DebtInstrumentAnnualPrincipalPayment
2000000 usd
CY2023Q4 hcti Warrants Recognized Cost
WarrantsRecognizedCost
0 usd
CY2022Q4 hcti Warrants Recognized Cost
WarrantsRecognizedCost
0 usd
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
954000 usd
CY2022 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1087000 usd
CY2023 us-gaap Short Term Debt Interest Rate Increase
ShortTermDebtInterestRateIncrease
0.01 pure
CY2023Q4 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
2317000 usd
CY2022Q4 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
2412000 usd
CY2023 hcti Percentage Of Promissory Convertible Note
PercentageOfPromissoryConvertibleNote
0.15 pure
CY2023 hcti Fund Repayable
FundRepayable
1100000 usd
CY2023Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
2209000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Maturity Date
DebtSecuritiesAvailableForSaleMaturityDate
2022-04-30
CY2023 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
2209000 usd
CY2023 hcti Outstanding Amount Of Short Term Borrowings
OutstandingAmountOfShortTermBorrowings
0 usd
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3322000 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2578000 usd
CY2023Q4 hcti Deferred Tax Assets Tax Deferred Expense Stockbased Compensation
DeferredTaxAssetsTaxDeferredExpenseStockbasedCompensation
18000 usd
CY2022Q4 hcti Deferred Tax Assets Tax Deferred Expense Stockbased Compensation
DeferredTaxAssetsTaxDeferredExpenseStockbasedCompensation
27000 usd
CY2022Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
292000 usd
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
3305000 usd
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2843000 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3305000 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2843000 usd
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
35000 usd
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
63000 usd
CY2023 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
35000 usd
CY2022 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
63000 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
35000 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
63000 usd
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
408514 shares
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
164000 shares
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
31986 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
323500 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
276500 shares
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
17000 usd
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
257000 usd
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
490000 usd
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M12D
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
17000 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
257000 usd
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12339000 usd
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9610000 usd
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4228741 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3659095 shares
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.92
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.63
CY2023 us-gaap Retail Land Sales Installment Method Sales Value
RetailLandSalesInstallmentMethodSalesValue
250000 usd
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
205077 shares
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
3025000 usd
CY2023 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
usd
CY2023Q4 us-gaap Goodwill
Goodwill
usd
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
usd
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.63
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.92
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3659095 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4228741 shares
CY2023 hcti Income From Ppp
IncomeFromPPP
usd
CY2023 hcti Interest On Leases Paymentpayroll Protection Program
InterestOnLeasesPaymentpayrollProtectionProgram
usd
CY2023 hcti Warrants Fair Valuation Expenses
WarrantsFairValuationExpenses
usd
CY2022 hcti Warrants Fair Valuation Expenses
WarrantsFairValuationExpenses
usd
CY2023 us-gaap Other Noncash Expense
OtherNoncashExpense
usd
CY2022 us-gaap Other Noncash Expense
OtherNoncashExpense
usd
CY2023 hcti Contingents Consideration
ContingentsConsideration
usd
CY2022 hcti Contingents Consideration
ContingentsConsideration
usd
CY2023 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
usd
CY2023 us-gaap Payments To Acquire Interest In Subsidiaries And Affiliates
PaymentsToAcquireInterestInSubsidiariesAndAffiliates
usd
CY2022 us-gaap Payments To Acquire Interest In Subsidiaries And Affiliates
PaymentsToAcquireInterestInSubsidiariesAndAffiliates
usd
CY2023 hcti Increase In Capital
IncreaseInCapital
usd
CY2023 hcti Taxes Paid
TaxesPaid
usd
CY2023 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
usd
CY2023 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
CY2023 hcti Increase In Paycheck Protection Program Loans
IncreaseInPaycheckProtectionProgramLoans
usd
CY2022 hcti Increase In Paycheck Protection Program Loans
IncreaseInPaycheckProtectionProgramLoans
usd
CY2022Q4 hcti Lease Expense
LeaseExpense
usd
CY2023 hcti Additions Lease Expenses
AdditionsLeaseExpenses
usd
CY2022 hcti Additions Lease Expenses
AdditionsLeaseExpenses
usd
CY2023 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
usd
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
usd
CY2023Q4 hcti Lease Expense
LeaseExpense
usd
CY2022Q4 hcti Lease Expense
LeaseExpense
usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
usd
CY2023 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
usd
CY2023Q4 hcti Business Combination Recognized Working Capital
BusinessCombinationRecognizedWorkingCapital
usd
CY2023Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2023Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
usd
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
usd
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
usd
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
usd
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
usd
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
usd
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
usd
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
usd
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.63
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.92
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001839285

Files In Submission

Name View Source Status
0001213900-24-023562-index-headers.html Edgar Link pending
0001213900-24-023562-index.html Edgar Link pending
0001213900-24-023562.txt Edgar Link pending
0001213900-24-023562-xbrl.zip Edgar Link pending
f10k2023ex31-1_healthcare.htm Edgar Link pending
f10k2023ex31-2_healthcare.htm Edgar Link pending
f10k2023ex32-1_healthcare.htm Edgar Link pending
f10k2023ex32-2_healthcare.htm Edgar Link pending
f10k2023ex4-4_healthcare.htm Edgar Link pending
f10k2023_healthcare.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hcti-20231231.xsd Edgar Link pending
image_001.jpg Edgar Link pending
image_002.jpg Edgar Link pending
image_003.jpg Edgar Link pending
image_004.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
hcti-20231231_cal.xml Edgar Link unprocessable
hcti-20231231_def.xml Edgar Link unprocessable
hcti-20231231_lab.xml Edgar Link unprocessable
hcti-20231231_pre.xml Edgar Link unprocessable
f10k2023_healthcare_htm.xml Edgar Link completed
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable